Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.
The celebrity dermatologist talks about finding her moment of clarity in finding relief for her eczema symptoms and how she ...
Loss of response to biologics is common, with therapeutic drug monitoring used to identify treatment failures. Ongoing research is crucial to optimize biologic therapies and identify the best ...
Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients ...
Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.
Another novel therapy gaining attention is Nemluvio, an oral medication that works ... Adbry is a new biologic therapy specifically developed for patients with moderate to severe atopic dermatitis ...
Topical PF-07038124 showed superior efficacy and safety in treating mild to moderate atopic dermatitis and ... approach could significantly reduce biologic drug prices for psoriasis, aligning ...
IGA 0 or 1 and EASI 75 have been determined by the U.S. Food and Drug Administration ... systemic injectable biologic ...
Another novel therapy gaining attention is Nemluvio, an oral medication ... Adbry is a new biologic therapy specifically developed for patients with moderate to severe atopic dermatitis (eczema).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results